Fungal co-infection in COVID-19 patients: Should we be concerned?
Rev Iberoam Micol
; 37(2): 41-46, 2020.
Artículo
en Inglés
| MEDLINE | ID: covidwho-756851
ABSTRACT
Critically ill COVID-19 patients have higher pro-inflammatory (IL-1, IL-2, IL-6, tumor necrosis alpha) and anti-inflammatory (IL-4, IL-10) cytokine levels, less CD4 interferon-gamma expression, and fewer CD4 and CD8 cells. This severe clinical situation increases the risk of serious fungal infections, such as invasive pulmonary aspergillosis, invasive candidiasis or Pneumocystis jirovecii pneumonia. However, few studies have investigated fungal coinfections in this population. We describe an update on published reports on fungal coinfections and our personal experience in three Spanish hospitals. We can conclude that despite the serious disease caused by SARS-CoV-2 in many patients, the scarcity of invasive mycoses is probably due to the few bronchoscopies and necropsies performed in these patients because of the high risk in aerosol generation. However, the presence of fungal markers in clinically relevant specimens, with the exception of bronchopulmonary colonization by Candida, should make it advisable to early implement antifungal therapy.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Neumonía por Pneumocystis
/
Neumonía Viral
/
Infecciones por Coronavirus
/
Aspergilosis Pulmonar Invasiva
/
Candidiasis Invasiva
/
Coinfección
/
Betacoronavirus
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
Límite:
Humanos
País/Región como asunto:
Europa
Idioma:
Inglés
Revista:
Rev Iberoam Micol
Asunto de la revista:
Microbiologia
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS